GlycoMimetics price target lowered to $8 from $13 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on GlycoMimetics to $8 from $13 and keeps a Buy rating on the shares. The analyst cites dilution from the capital raise and a pushing out of the launch expectation for uproleselan for the target drop.